Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit

BACKGROUND: Almost 100 novel cancer medicines have been approved in Europe over the last decade. Limited public health care resources in countries in Central and Eastern Europe (CEE) call for a prioritization of access to effective medicines. We investigated how both reimbursement status and waiting...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmarcher, T., Szilagyiova, P., Gustafsson, A., Dolezal, T., Rutkowski, P., Baxter, C., Karamousouli, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485399/
https://www.ncbi.nlm.nih.gov/pubmed/37413761
http://dx.doi.org/10.1016/j.esmoop.2023.101593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485399/
https://www.ncbi.nlm.nih.gov/pubmed/37413761
http://dx.doi.org/10.1016/j.esmoop.2023.101593

Ejemplares similares